Heaviside Industries Secures $60 Million in Latest Series B Funding Round

Heaviside Industries secured $60 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Heaviside Industries Raises $60 million in Funding

Heaviside Industries Announces Nammo Partnership, $60 Million Series B. The Cambridge-based biotech is developing in vivo CAR therapies for autoimmune disease and oncology using an mRNA-LNP platform that engineers immune cells directly inside the body, with the funding going toward advancing its CD19-targeted autoimmune program into the clinic, expanding its dual CAR CD19 x Heaviside emerges from stealth with $28M Series A — Heaviside Industries.

Investors Behind the Funding

The round was backed by Khosla Ventures. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Heaviside Industries operates in Healthcare & Life Sciences. Heaviside Industries's financing adds to recent private-market activity.

Strategic Use of Funds

them very quickly

Looking Ahead

Heaviside Industries Announces Nammo Partnership, $60 Million Series B

Source reference: original announcement/article.